학술논문
P65 Cost-Effectiveness of Every Two Month Cabotegravir Long-Acting (CAB-LA) Compared with Daily Oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for PRE-Exposure Prophylaxis (PREP) to Prevent HIV-1 Infection in the United States
Document Type
Abstract
Author
Source
In Value in Health July 2022 25(7) Supplement:S301-S301
Subject
Language
ISSN
1098-3015